Kazia Therapeutics (NASDAQ:KZIA) Coverage Initiated at Maxim Group

Stock analysts at Maxim Group started coverage on shares of Kazia Therapeutics (NASDAQ:KZIA) in a note issued to investors on Thursday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s target price suggests a potential upside of 114.29% from the company’s previous close.

Kazia Therapeutics Price Performance

NASDAQ:KZIA opened at $1.40 on Thursday. The company has a 50-day moving average of $2.56 and a 200-day moving average of $3.74. Kazia Therapeutics has a 52 week low of $1.31 and a 52 week high of $15.80.

Hedge Funds Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management acquired a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned approximately 51.66% of Kazia Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.